title: A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
abstract: OBJECTIVE
  To assess the efficacy of the 8-week therapy with esomeprazole 40 mg vs. pantoprazole 40 mg for healing erosive oesophagitis (EE) as part of a management study.
  
  
  METHODS
  Patients had a history of gastro-oesophageal reflux disease symptoms (> or =6 months) and had suffered heartburn on at least 4 of the 7 days preceding enrollment. Endoscopies were performed to grade EE severity using the Los Angeles (LA) classification system at baseline, 4 and 8 weeks (if unhealed at 4 weeks). Heartburn severity was recorded by patients on diary cards. The primary end point was healing of EE by week 8 of treatment.
  
  
  RESULTS
  Of 3170 patients randomized, the intent-to-treat population consisted of 3151 patients (63% male, mean age: 50.6 years, 27% Helicobacter pylori-positive). Esomeprazole 40 mg healed a significantly greater proportion of EE patients than pantoprazole 40 mg at both 4 weeks (life table estimates: esomeprazole 81%, pantoprazole 75%, P < 0.001) and 8 weeks (life table estimates: esomeprazole 96%, pantoprazole 92%, P < 0.001). The median time to reach sustained heartburn resolution was 6 days in patients receiving esomeprazole and 8 days with pantoprazole (P < 0.001).
  
  
  CONCLUSIONS
  Esomeprazole 40 mg is more effective than pantoprazole 40 mg for healing EE and providing resolution of associated heartburn.
authors.affiliation: Medical Department, Ev.Jung-Stilling Krankenhaus, D-57074 Siegen, Germany. j.labenz@t-online.de
authors.forename: J
authors.initials: J
authors.lastname: Labenz
authors.forename: D
authors.initials: D
authors.lastname: Armstrong
authors.forename: K
authors.initials: K
authors.lastname: Lauritsen
authors.forename: P
authors.initials: P
authors.lastname: Katelaris
authors.forename: S
authors.initials: S
authors.lastname: Schmidt
authors.forename: K
authors.initials: K
authors.lastname: Schütze
authors.forename: G
authors.initials: G
authors.lastname: Wallner
authors.forename: H
authors.initials: H
authors.lastname: Juergens
authors.forename: H
authors.initials: H
authors.lastname: Preiksaitis
authors.forename: N
authors.initials: N
authors.lastname: Keeling
authors.forename: E
authors.initials: E
authors.lastname: Nauclér
authors.forename: S
authors.initials: S
authors.lastname: Eklund
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D004311:Double-Blind Method; D064098:Esomeprazole / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D004941:Esophagitis / Q000188:drug therapy*; D005260:Female; D005764:Gastroesophageal Reflux / Q000209:etiology; D006356:Heartburn / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D013454:Sulfoxides / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D013454:Sulfoxides; D000077402:Pantoprazole; D064098:Esomeprazole